|Synergy Pharmaceuticals, Inc.|
420 Lexington Avenue
United States - Map
|Industry:||Drug Manufacturers - Other|
|Full Time Employees:||18|
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
|Dr. Gary S. Jacob Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Bernard F. Denoyer CPA, M.B.A.,
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
|Dr. Kunwar Shailubhai Ph.D.,
Chief Scientific Officer
|Dr. Laura Barrow Pharm. D.,
Sr. VP of Clinical Operations
|Dr. Stephen Comiskey Ph.D.,
VP of Product Devel.
|Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|